Nuvectis Pharma price to book ratio NVCT

Market value divided by the book value of the company's net assets, since 2022.

Today, Oct 23, 2026: 71.9×
4-year median: 10.1×
Against its 4-year history: 96th; percentile: 0 is its lowest day, 100 its highest
4-year range: 4.9× to 87.9×
Peer median: 2.3×

Nuvectis Pharma's price to book ratio is 71.9× as of Oct 23, 2026.

That is above its 4-year median of 10.1×, higher than on 96% of days in the last 4 years.

Over that time it ranged from 4.9× in Nov 2022 to 87.9× in Sep 2026.

The median for 10 large drugmakers of a similar size is 2.3×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	71.9×	8.7×	87.9×
2025	8.3×	6.4×	25.3×
2024	9.2×	6.9×	19.0×
2023	8.7×	5.3×	23.6×
2022	5.4×	4.9×	16.5×

Against its peers

Companies in Drug Manufacturers - General nearest Nuvectis Pharma's size, closest first, today.

Company	Price to book ratio
NVCTNuvectis Pharma	71.9×
CRMDCorMedix	1.3×
ZVRAZevra Therapeutics	2.7×
IRWDIronwood Pharmaceuticals	n/m
COLLCollegium Pharmaceutical	2.4×
PBYIPuma Biotechnology	4.1×
ABUSArbutus Biopharma	3.2×
ARVNArvinas	0.8×
AMPHAmphastar Pharmaceuticals	1.4×
OMEROmeros	n/m
PCRXPacira BioSciences	2.2×
Peer median	2.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Nuvectis Pharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.